Table 1 Description of the MARIE study population
Characteristics | Overall (N = 1,408) | Breast cancer deaths (N = 147) |
|---|---|---|
Age at diagnosis | Â | Â |
 50–54 years | 102 (7.2 %) | 11 (7.5 %) |
 55–59 years | 304 (21.6 %) | 25 (17.0 %) |
 60–64 years | 446 (31.7 %) | 51 (34.7 %) |
 65–69 years | 380 (27.0 %) | 38 (25.9 %) |
 ≥70 years | 176 (12.5 %) | 22 (15.0 %) |
Tumour size (cm) | Â | Â |
 ≤2 | 774 (55.0 %) | 36 (24.5 %) |
 >2 – ≤5 | 477 (33.9 %) | 65 (44.2 %) |
 >5 | 49 (3.5 %) | 11 (7.5 %) |
 Growth into chest wall | 43 (3.1 %) | 18 (12.2 %) |
 Neoadjuvant chemotherapy | 62 (4.4 %) | 16 (10.9 %) |
 Missings | 3 (0.2 %) | 1 (0.7 %) |
Nodal status (number of affected lymph nodes)a | Â | Â |
 0 | 901 (64.0 %) | 43 (29.3 %) |
 1–3 | 310 (22.0 %) | 39 (26.5 %) |
 4–9 | 70 (5.0 %) | 16 (10.9 %) |
 ≥10 | 61 (4.3 %) | 31 (21.1 %) |
 Missings | 4 (0.3 %) | 2 (1.4 %) |
Metastasis status | Â | Â |
 M0 | 1356 (96.3 %) | 112 (76.2 %) |
 M1 | 51 (3.6 %) | 34 (23.1 %) |
 Missings | 1 (0.1 %) | 1 (0.7 %) |
Histological gradinga | Â | Â |
 Grade 1 + 2 | 963 (68.4 %) | 57 (38.8 %) |
 Grade 3 + 4 | 376 (26.7 %) | 73 (49.7 %) |
 Missings | 7 (0.5 %) | 1 (0.7 %) |
Hormone receptor statusa | Â | Â |
 ER+PR+ | 850 (60.4 %) | 60 (40.8 %) |
 ER+PR− or ER−PR+ | 271 (19.2 %) | 29 (19.7 %) |
 ER−PR− | 224 (15.9 %) | 42 (28.6 %) |
 Missings | 1 (0.1 %) | -- |
Mode of detection | Â | Â |
 Self-detected | 794 (56.4 %) | 119 (81.0 %) |
 Routine examination | 609 (43.3 %) | 28 (19.0 %) |
 Missings | 5 (0.4 %) | -- |
Radiotherapy | Â | Â |
 No | 288 (20.5 %) | 51 (34.7 %) |
 Yes | 1107 (78.6 %) | 94 (63.9 %) |
 Missings | 13 (0.9 %) | 2 (1.4 %) |
Chemotherapy | Â | Â |
 No | 718 (51.0 %) | 42 (28.6 %) |
 Yes | 675 (47.9 %) | 103 (70.1 %) |
  Anthracycline-based | 485 (71.9 %) | 74 (71.8 %) |
 Missings | 15 (1.1 %) | 3 (2.0 %) |
Adult body mass index (BMI) | Â | Â |
 ≥25 kg/m2 | 360 (25.6 %) | 54 (36.7 %) |
 Missings | -- | -- |
Smoking status | Â | Â |
 Never smokers | 800 (56.8 %) | 83 (56.5 %) |
 Former smokers | 351 (24.9 %) | 34 (23.1 %) |
 Current smokers | 257 (18.3 %) | 30 (20.4 %) |
Menopausal hormone therapy | Â | Â |
 Yes, at diagnosis | 594 (42.2 %) | 34 (23.1 %) |
 Missings | 11 (0.8 %) | 3 (2.0 %) |